author-photo

J. A. Cohen

Cleveland Clinic

36

Papers

1636

Citations

Citation Trend

Filter By

Papers (28) Sort By

Journal Conference Others

Analysis of lymphocyte counts and infection rates with fingolimod in patients with primary progressive multiple sclerosis over the INFORMS trial (P1.387)

2018 Neurology
Show All
- Source
- Cite
- Save
Citations (0)
Design and rationale of the determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis (DELIVER-MS) trial

2018 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)
Long-term Prognosis of Disease Evolution and Evidence for Sustained Fingolimod Treatment Effect by Blood Neurofilament Light in RRMS Patients (S24.004)

2018 Neurology
Show All
- Source
- Cite
- Save
Citations (0)
Alemtuzumab CARE-MS II 5-year follow-up

2017
Show All
- Source
- Cite
- Save
Citations (7)
Experiences of care among dually eligible beneficiaries with and without cancer: SEER-CAHPS, 2007-2013

2016
Show All
- Source
- Cite
- Save
Citations (0)
Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).

2016 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (11)
Quality of life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II

2015 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (1)
Effect of fingolimod versus interferon-beta1a on neda-4 (no evidence of disease activity or worsening) in the transforms study

2015 Journal of the Neurological Sciences
Show All
- Source
- Cite
- Save
Citations (0)
Rationale for EDSS-Plus, the Primary Composite Endpoint of Disability Progression in the ASCEND Phase 3 Study of Natalizumab for Secondary Progressive Multiple Sclerosis: A Post Hoc Analysis of IMPACT Study Data (P7.240)

2015 Neurology
Show All
- Source
- Cite
- Save
Citations (0)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

2014 Journal of Neurology
Show All
- Source
- Cite
- Save
Citations (139)